Expert consensus for the diagnosis and treatment of sterile intraocular inflammation after intraocular drug delivery (2025)_Chinese Journal of Ocular Fundus Diseases

Authors：

 Fundus Disease Group of Ophthalmological Society of Chinese Medical Association ,  Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association , Expert Group of Expert Consensus for the Diagnosis Treatment of SterileIntraocular Inflammation after Intraocular Drug Delivery (2025)

Corresponding author：

Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Email: dr_lixiaoxin@163.com; Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association, Email: drxuxun@sjtu.edu.cn

Keywords：

Intraocular drug delivery; Sterile intraocular inflammation; Evidence-based medicine; Diagnosis and treatment; Expert consensus

DOI：

10.3760/cma.j.cn511434-20250617-00274

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In recent years, anti-vascular endothelial growth factor (VEGF) therapy has become first line treatment for a variety of clinical conditions, including wet age related macular degeneration, macular edema secondary to retinal vein occlusion, diabetic macular edema and proliferative diabetic retinopathy. With the successive launch of new formulations such as high-dose anti-VEGF drugs and gene therapy in China, sterile intraocular inflammation (SIOI) after intraocular drug delivery has gradually come into public view and warranted attention. On the other hand, a variety of drugs that have been used in ophthalmic clinics for years, including prophylactic anti-infective drugs (such as vancomycin) and glucocorticoids (such as dexamethasone implants), have also been reported of SIOI occurrence. To avoid and alleviate the negative impact of SIOI on the visual function of the affected eyes, a systematic and standardized SIOI management system is urgently needed. For this reason, the Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Committee of Ophthalmologist Branch of Chinese Medical Doctor Association, and Expert Group of Expert consensus for the diagnosis and treatment of sterile intraocular inflammation after intraocular drug delivery (2025) put forward recommended opinions on seven key clinical issues. Based on the latest evidence based medical evidence, combined with international guidelines/consensuses and the current situation of social and economic development in China, they made recommendations on aspects of SIOI, including the incidence and timing, clinical manifestations, related factors and population identification, perioperative monitoring measures, and intervention strategies and prognosis after the occurrence of SIOI, thus forming the Expert consensus for the diagnosis and treatment of sterile intraocular inflammation after intraocular drug delivery (2025). The formulation of this consensus aims to enhance the awareness and understanding of SIOI among ophthalmologists specializing in retinal diseases, provide evidence-based guidance and decision-making references for the early identification and standardized management of SIOI in clinical practice, and further improve the quality control system of intraocular injection therapy in China, thereby ensuring patient safety.

Citation： Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association, Expert Group of Expert Consensus for the Diagnosis Treatment of SterileIntraocular Inflammation after Intraocular Drug Delivery (2025). Expert consensus for the diagnosis and treatment of sterile intraocular inflammation after intraocular drug delivery (2025). Chinese Journal of Ocular Fundus Diseases, 2025, 41(7): 492-506. doi: 10.3760/cma.j.cn511434-20250617-00274 Copy

1.	Moraru AD, Danielescu C, Iorga RE. Review of guideline recommendations for optimal anti-VEGF therapy in age-related macular degeneration[J/OL]. Life (Basel), 2024, 14(10): 1220[2024-09-24]. https://pubmed.ncbi.nlm.nih.gov/39459520/. DOI: 10.3390/life14101220.
2.	Galvez-Olortegui J, Bouchikh-El Jarroudi R, Silva-Ocas I, et al. Systematic review of clinical practice guidelines for the diagnosis and management of retinal vein occlusion[J]. Eye (Lond), 2024, 38(9): 1722-1733. DOI: 10.1038/s41433-024-03008-1.
3.	Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings[J]. Ophthalmology, 2018, 125(10): 1608-1622. DOI: 10.1016/j.ophtha.2018.04.007.
4.	Beuran DI, Macovei ML, Cornăcel C, et al. Sterile endophthalmitis after intravitreal injection of triamcinolone acetonide: case report and literature review[J]. Rom J Ophthalmol, 2024, 68(1): 2-7. DOI: 10.22336/rjo.2024.02.
5.	Montolío-Marzo S, Vidal-Oliver L, Montolío-Marzo E, et al. Differential diagnosis of endophthalmitis after intravitreal drug injection for age related macular degeneration: sterile vs. infectious[J]. Arch Soc Esp Oftalmol (Engl Ed), 2023, 98(7): 367-376. DOI: 10.1016/j.oftale.2023.04.014.
6.	Anderson WJ, da Cruz NFS, Lima LH, et al. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review[J]. Int J Retina Vitreous, 2021, 7(1): 37. DOI: 10.1186/s40942-021-00307-7.
7.	Cox JT, Eliott D, Sobrin L. Inflammatory complications of intravitreal anti-VEGF injections[J]. J Clin Med, 2021, 10(5): 981. DOI: 10.3390/jcm10050981.
8.	Banou L, Sarrafpour S, Teng CC, et al. Ocular gene therapy: an overview of viral vectors, immune responses, and future directions[J]. Yale J Biol Med, 2024, 97(4): 491-503. DOI: 10.59249/HWID7537.
9.	Gautam M, Gupta R, Singh P, et al. Intracameral drug delivery: a review of agents, indications, and outcomes[J]. J Ocul Pharmacol Ther, 2023, 39(2): 102-116. DOI: 10.1089/jop.2022.0144.
10.	Zeng S, Liu XL. A review of ten years of experience using dexamethasone intravitreal implants (Ozurdex) for uveitis[J]. Eur Rev Med Pharmacol Sci, 2023, 27(5): 1743-1758. DOI: 10.26355/eurrev_202303_31535.
11.	Abdi F, Mohammadi SS, Falavarjani KG. Intravitreal methotrexate[J]. J Ophthalmic Vis Res, 2021, 16(4): 657-669. DOI: 10.18502/jovr.v16i4.9756.
12.	陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版)[J]. 中华医学杂志, 2022, 102(10): 697-703. DOI: 10.3760/cma.j.cn112137-20211228-02911.Chen YL, Yang KH, Wang XQ, et al. Guiding principles for the formulation/revision of clinical diagnosis and treatment guidelines in China (2022 Edition)[J]. Natl Med J China, 2022, 102(10): 697-703. DOI: 10.3760/cma.j.cn112137-20211228-02911.
13.	孙鑫, 李玲, 李舍予, 等. 促进高质量临床实践指南快速制订与有效使用: MAGIC体系与中国行动[J]. 中国循证医学杂志, 2020, 20(1): 2-6. DOI: 10.7507/1672-2531.201909110.Sun X, Li L, Li SY, et al. Promoting the rapid creation and effective use of high-quality clinical practice guidelines: MAGIC system and China initiative[J]. Chinese Journal of Evidence-Based Medicine, 2020, 20(1): 2-6. DOI: 10.7507/1672-2531.201909110.
14.	Witkin AJ, Shah AR, Engstrom RE, et al. Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin[J]. Ophthalmology, 2015, 122(7): 1438-1451. DOI: 10.1016/j.ophtha.2015.03.016.
15.	Witkin AJ, Chang DF, Jumper JM, et al. Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteristics of 36 eyes[J]. Ophthalmology, 2017, 124(5): 583-595. DOI: 10.1016/j.ophtha.2016.11.042.
16.	Schwartz SG, Relhan N, O'Brien TP, et al. A complication associated with the use of prophylactic intracameral antibiotics: hemorrhagic occlusive retinal vasculitis[J]. Ophthalmology, 2017, 124(5): 578-579. DOI: 10.1016/j.ophtha.2017.01.038.
17.	Todorich B, Faia LJ, Thanos A, et al. Vancomycin-associated hemorrhagic occlusive retinal vasculitis: a clinical-pathophysiological analysis[J]. Am J Ophthalmol, 2018, 188: 131-140. DOI: 10.1016/j.ajo.2018.01.030.
18.	Matovic K, Mekjavic PJ, Groznik AL, et al. Vancomycin-associated hemorrhagic occlusive retinal vasculitis: a case series and systematic review[J]. Ophthalmic Surg Lasers Imaging Retina, 2022, 53(12): 702-712. DOI: 10.3928/23258160-20221026-03.
19.	Mason RH, Ballios BG, Yan P, et al. Noninfectious endophthalmitis following intravitreal triamcinolone acetonide: clinical case and literature review[J]. Can J Ophthalmol, 2020, 55(6): 471-479. DOI: 10.1016/j.jcjo.2020.06.002.
20.	Henry CR, Shah M, Barakat MR, et al. Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA)[J]. Br J Ophthalmol, 2022, 106(6): 802-806. DOI: 10.1136/bjophthalmol-2020-318019.
21.	Barakat MR, Wykoff CC, Gonzalez V, et al. Suprachoroidal CLS-TA plus intravitreal aflibercept for diabetic macular edema: a randomized, double-masked, parallel-design, controlled study[J]. Ophthalmol Retina, 2021, 5(1): 60-70. DOI: 10.1016/j.oret.2020.08.007.
22.	Zakaria YG, Salman AG, Said AMA, et al. Suprachoroidal versus intravitreal triamcinolone acetonide for the treatment of diabetic macular edema[J]. Clin Ophthalmol, 2022, 16: 733-746. DOI: 10.2147/OPTH.S351853.
23.	Korobelnik JF, Kodjikian L, Delcourt C, et al. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France[J]. Graefe's Arch Clin Exp Ophthalmol, 2016, 254(12): 2307-2318. DOI: 10.1007/s00417-016-3394-y.
24.	Rajesh B, Zarranz-Ventura J, Fung AT, et al. Safety of 6000 intravitreal dexamethasone implants[J]. Br J Ophthalmol, 2020, 104(1): 39-46. DOI: 10.1136/bjophthalmol-2019-313991.
25.	Dobler E, Mohammed BR, Chavan R, et al. Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results[J]. Eye (Lond), 2023, 37(11): 2310-2315. DOI: 10.1038/s41433-022-02338-2.
26.	Christensen LF, Hassing AK, Klefter ON, et al. Efficacy and safety of fluocinolone acetonide 0.19 mg intravitreal implant for the treatment of non-infectious uveitis: a systematic review of real-world evidence[J]. Ocul Immunol Inflamm, 2024, 33(4): 683-694. DOI: 10.1080/09273948.2024.2435472.
27.	Daien V, Nguyen V, Essex RW, et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration[J]. Ophthalmology, 2018, 125(1): 66-74. DOI: 10.1016/j.ophtha.2017.07.005.
28.	Williams PD, Chong D, Fuller T, et al. Noninfectious vitritis after intravitreal injection of anti-VEGF agents: variations in rates and presentation by medication[J]. Retina, 2016, 36(5): 909-913. DOI: 10.1097/IAE.0000000000000801.
29.	Yang F, Hu R. Efficacy and safety of intravitreal conbercept and triamcinolone acetonide for wet age-related macular degeneration in China: a meta-analysis[J]. Int Ophthalmol, 2024, 44(1): 424. DOI: 10.1007/s10792-024-03346-9.
30.	Baumal CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after Brolucizumab treatment[J]. Ophthalmol Retina, 2021, 5(6): 519-527. DOI: 10.1016/j.oret.2020.09.020.
31.	Cozzi M, Ziegler A, Fasler K, et al. Sterile intraocular inflammation associated with faricimab[J]. JAMA Ophthalmol, 2024, 142(11): 1028-1036. DOI: 10.1001/jamaophthalmol.2024.3828.
32.	Matsumoto H, Hoshino J, Numaga S, et al. Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration[J]. Jpn J Ophthalmol, 2024, 68(5): 531-537. DOI: 10.1007/s10384-024-01107-w.
33.	Hashiya N, Maruko I, Miyaguchi Y, et al. Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report[J]. BMC Ophthalmol, 2025, 25(1): 42. DOI: 10.1186/s12886-024-03827-6.
34.	Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement[J]. Ophthalmology, 2002, 109(9): 1709-1716. DOI: 10.1016/s0161-6420(02)01125-9.
35.	Zhou N, Xu X, Liu Y, et al. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma[J]. Eye (Lond), 2022, 36(7): 1448-1455. DOI: 10.1038/s41433-021-01657-0.
36.	Razzaghpour N, Najafi A, Sabouri M R, et al. Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month study[J]. Med Hypothesis Discov Innov Ophthalmol, 2023, 12(3): 150-156. DOI: 10.51329/mehdiophthal1480.
37.	Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2017, 390(10097): 849-860. DOI: 10.1016/S0140-6736(17)31868-8.
38.	Kiraly P, Cottriall CL, Taylor LJ, et al. Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center[J/OL]. Biomolecules, 2023, 13(10): 1484[2023-10-05]. https://pubmed.ncbi.nlm.nih.gov/37892166/. DOI: 10.3390/biom13101484.
39.	He X, Cao W, Wang Z, et al. Efficacy evaluation of tissue plasminogen activator with anti-vascular endothelial growth factor drugs for submacular hemorrhage treatment: a meta-analysis[J/OL]. J Clin Med, 2023, 12(3): 1035[2023-01-29]. https://pubmed.ncbi.nlm.nih.gov/36769682/. DOI: 10.3390/jcm12031035.
40.	Treumer F, Wienand S, Purtskhvanidze K, et al. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF[J]. Graefe's Arch Clin Exp Ophthalmol, 2017, 255(6): 1115-1123. DOI: 10.1007/s00417-017-3620-2.
41.	Greenberg JP, Belin P, Butler J, et al. Aflibercept-related sterile intraocular inflammation outcomes[J]. Ophthalmol Retina, 2019, 3(9): 753-759. DOI: 10.1016/j.oret.2019.04.006.
42.	Witkin AJ, Hahn P, Murray TG, et al. Occlusive retinal vasculitis following intravitreal Brolucizumab[J]. J Vitreoretin Dis, 2020, 4(4): 269-279. DOI: 10.1177/2474126420930863.
43.	Mares V, Veloso C, Nehemy MB. Vancomycin-associated hemorrhagic occlusive retinal vasculitis masquerading as central retinal vein occlusion[J/OL]. Arq Bras Oftalmol, 2023, 87(4): e2022-2032[2023-03-24]. https://pubmed.ncbi.nlm.nih.gov/36995817/. DOI: 10.5935/0004-2749.2022-0132.
44.	El Gendy HA. Vancomycin-associated retinal hemorrhages in pediatric age group: a case report[J/OL]. Am J Ophthalmol Case Rep, 2020, 20: 100880[2020-08-21]. https://pubmed.ncbi.nlm.nih.gov/32913922/. DOI: 10.1016/j.ajoc.2020.100880.
45.	Nowroozzadeh MH, Hajipourkhorasani M. Increased risk of retinal vasculitis may be associated with aflibercept 8 mg: a pharmacovigilance analysis of the FAERS database[J]. Ocul Immunol Inflamm, 2025, 6: 1-3. DOI: 10.1080/09273948.2025.2476061.
46.	Parakh S, Bhatt V, Das S, et al. Intraocular inflammation following intravitreal faricimab injection in neovascular age-related macular degeneration[J/OL]. Cureus, 2024, 16(12): e75937[2024-12-18]. https://pubmed.ncbi.nlm.nih.gov/39830553/. DOI: 10.7759/cureus.75937.
47.	Lee YM, Gurung R, Gilhotra JS, et al. Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: a case report and review of literature[J]. Eye Vis (Lond), 2024, 11(1): 48. DOI: 10.1186/s40662-024-00416-y.
48.	Perez Y, Neri P, Pichi F, et al. Multimodal imaging in retinal vasculitis[J]. Ophthalmologica, 2024, 247(4): 203-213. DOI: 10.1159/000540647.
49.	Sharma A, Kumar N, Parachuri N, et al. Immunogenicity: clouding the future of intravitreal therapy[J]. Ocul Immunol Inflamm, 2023, 31(9): 1746-1749. DOI: 10.1080/09273948.2022.2139273.
50.	Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals[J]. Ther Adv Drug Saf, 2011, 2(3): 113-128. DOI: 10.1177/2042098611406318.
51.	Kim HM, Woo SJ. Immunogenicity and potential for intraocular inflammation of intravitreal anti-VEGF drugs[J/OL]. Curr Ther Res Clin Exp, 2024, 100: 100742[2024-03-14]. https://pubmed.ncbi.nlm.nih.gov/38617894/. DOI: 10.1016/j.curtheres.2024.100742.
52.	Ghoraba HH, Akhavanrezayat A, Karaca I, et al. Ocular gene therapy: a literature review with special focus on immune and inflammatory responses[J]. Clin Ophthalmol, 2022, 16: 1753-1771. DOI: 10.2147/OPTH.S364200.
53.	Chan YK, Dick AD, Hall SM, et al. Inflammation in viral vector-mediated ocular gene therapy: a review and report from a workshop hosted by the foundation fighting blindness, 9/2020[J]. Transl Vis Sci Technol, 2021, 10(4): 3. DOI: 10.1167/tvst.10.4.3.
54.	Bucher K, Rodriguez-Bocanegra E, Dauletbekov D, et al. Immune responses to retinal gene therapy using adeno-associated viral vectors-implications for treatment success and safety[J/OL]. Prog Retin Eye Res, 2021, 83: 100915[2020-10-15]. https://pubmed.ncbi.nlm.nih.gov/33069860/. DOI: 10.1016/j.preteyeres.2020.100915.
55.	Mehta N, Robbins DA, Yiu G, et al. Ocular inflammation and treatment emergent adverse events in retinal gene therapy[J]. Int Ophthalmol Clin, 2021, 61(3): 151-177. DOI: 10.1097/IIO.0000000000000366.
56.	Menia NK, Alcibahy Y, Pichi F, et al. An update on noninfectious retinal vasculitis[J]. Ophthalmologica, 2024, 5: 1-14. DOI: 10.1159/000539608.
57.	Lee K, Lee S, Jung S, et al. Analysis of ocular fluid in patients with ranibizumab-recalcitrant neovascular age-related macular degeneration who have serum anti-ranibizumab antibodies[J]. Graefe's Arch Clin Exp Ophthalmol, 2023, 261(12): 3581-3587. DOI: 10.1007/s00417-023-06146-6.
58.	Diack C, Gibiansky L, Jaminion F, et al. Ocular pharmacokinetics of Faricimab following intravitreal administration in patients with retinal disease[J]. Transl Vis Sci Technol, 2024, 13(11): 14. DOI: 10.1167/tvst.13.11.14.
59.	Yeung IY, Popp NA, Chan CC, et al. The role of sex in uveitis and ocular inflammation[J]. Int Ophthalmol Clin, 2015, 55(3): 111-131. DOI: 10.1097/IIO.0000000000000072.
60.	Sen HN, Davis J, Ucar D, et al. Gender disparities in ocular inflammatory disorders[J]. Curr Eye Res, 2015, 40(2): 146-161. DOI: 10.3109/02713683.2014.932388.
61.	Witkin AJ, Hahn P, Murray TG, et al. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis[J]. J Vitreoretin Dis, 2021, 5(4): 326-332. DOI: 10.1177/2474126420975303.
62.	Hikichi T. Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation[J]. Graefe's Arch Clin Exp Ophthalmol, 2022, 260(8): 2529-2535. DOI: 10.1007/s00417-022-05611-y.
63.	Eriş E, Perente I, Vural E, et al. Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema[J]. Int Ophthalmol, 2019, 39(7): 1575-1580. DOI: 10.1007/s10792-018-0977-0.
64.	Lin D, Hu J, Wu K, et al. Synergistic effect of combined sub-tenon Triamcinolone and intravitreal anti-VEGF therapy for uveitic macular edema[J]. Drug Des Devel Ther, 2022, 16: 1055-1066. DOI: 10.2147/DDDT.S353251.
65.	张峥, 杨滢瑞. 年龄相关性黄斑变性玻璃体腔内注药术围术期基于微视频的回授法健康教育效果分析[J]. 河南外科学杂志, 2024, 30(4): 158-161.Zhang Z, Yang YR. Analysis of the health education effect based on micro-video feedback method during the perioperative period of intravitreal injection for age-related macular degeneration[J]. Henan Journal of Surgery, 2024, 30(4): 158-161.
66.	Al Qassimi N, Kozak I, Al Karam M, et al. Management of diabetic macular edema: guidelines from the emirates society of ophthalmology[J]. Ophthalmol Ther, 2022, 11(5): 1937-1950. DOI: 10.1007/s40123-022-00547-2.
67.	中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病学组. 我国主要眼底病慢病管理专家共识[J]. 中华眼底病杂志, 2024, 40(4): 253-263. DOI: 10.3760/cma.j.cn511434-20240220-00076.Retinal Disease Group, Ophthalmology Branch of Chinese Medical Association, Retinal Disease Group, Ophthalmology Branch of Chinese Medical Doctor Association. National consensus on the management of major chronic fundus diseases in China: a modified Delphi approach[J]. Chin J Ocul Fundus Dis, 2024, 40(4): 253-263. DOI: 10.3760/cma.j.cn511434-20240220-00076.

1. Moraru AD, Danielescu C, Iorga RE. Review of guideline recommendations for optimal anti-VEGF therapy in age-related macular degeneration[J/OL]. Life (Basel), 2024, 14(10): 1220[2024-09-24]. https://pubmed.ncbi.nlm.nih.gov/39459520/. DOI: 10.3390/life14101220.
2. Galvez-Olortegui J, Bouchikh-El Jarroudi R, Silva-Ocas I, et al. Systematic review of clinical practice guidelines for the diagnosis and management of retinal vein occlusion[J]. Eye (Lond), 2024, 38(9): 1722-1733. DOI: 10.1038/s41433-024-03008-1.
3. Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings[J]. Ophthalmology, 2018, 125(10): 1608-1622. DOI: 10.1016/j.ophtha.2018.04.007.
4. Beuran DI, Macovei ML, Cornăcel C, et al. Sterile endophthalmitis after intravitreal injection of triamcinolone acetonide: case report and literature review[J]. Rom J Ophthalmol, 2024, 68(1): 2-7. DOI: 10.22336/rjo.2024.02.
5. Montolío-Marzo S, Vidal-Oliver L, Montolío-Marzo E, et al. Differential diagnosis of endophthalmitis after intravitreal drug injection for age related macular degeneration: sterile vs. infectious[J]. Arch Soc Esp Oftalmol (Engl Ed), 2023, 98(7): 367-376. DOI: 10.1016/j.oftale.2023.04.014.
6. Anderson WJ, da Cruz NFS, Lima LH, et al. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review[J]. Int J Retina Vitreous, 2021, 7(1): 37. DOI: 10.1186/s40942-021-00307-7.
7. Cox JT, Eliott D, Sobrin L. Inflammatory complications of intravitreal anti-VEGF injections[J]. J Clin Med, 2021, 10(5): 981. DOI: 10.3390/jcm10050981.
8. Banou L, Sarrafpour S, Teng CC, et al. Ocular gene therapy: an overview of viral vectors, immune responses, and future directions[J]. Yale J Biol Med, 2024, 97(4): 491-503. DOI: 10.59249/HWID7537.
9. Gautam M, Gupta R, Singh P, et al. Intracameral drug delivery: a review of agents, indications, and outcomes[J]. J Ocul Pharmacol Ther, 2023, 39(2): 102-116. DOI: 10.1089/jop.2022.0144.
10. Zeng S, Liu XL. A review of ten years of experience using dexamethasone intravitreal implants (Ozurdex) for uveitis[J]. Eur Rev Med Pharmacol Sci, 2023, 27(5): 1743-1758. DOI: 10.26355/eurrev_202303_31535.
11. Abdi F, Mohammadi SS, Falavarjani KG. Intravitreal methotrexate[J]. J Ophthalmic Vis Res, 2021, 16(4): 657-669. DOI: 10.18502/jovr.v16i4.9756.
12. 陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版)[J]. 中华医学杂志, 2022, 102(10): 697-703. DOI: 10.3760/cma.j.cn112137-20211228-02911.Chen YL, Yang KH, Wang XQ, et al. Guiding principles for the formulation/revision of clinical diagnosis and treatment guidelines in China (2022 Edition)[J]. Natl Med J China, 2022, 102(10): 697-703. DOI: 10.3760/cma.j.cn112137-20211228-02911.
13. 孙鑫, 李玲, 李舍予, 等. 促进高质量临床实践指南快速制订与有效使用: MAGIC体系与中国行动[J]. 中国循证医学杂志, 2020, 20(1): 2-6. DOI: 10.7507/1672-2531.201909110.Sun X, Li L, Li SY, et al. Promoting the rapid creation and effective use of high-quality clinical practice guidelines: MAGIC system and China initiative[J]. Chinese Journal of Evidence-Based Medicine, 2020, 20(1): 2-6. DOI: 10.7507/1672-2531.201909110.
14. Witkin AJ, Shah AR, Engstrom RE, et al. Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin[J]. Ophthalmology, 2015, 122(7): 1438-1451. DOI: 10.1016/j.ophtha.2015.03.016.
15. Witkin AJ, Chang DF, Jumper JM, et al. Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteristics of 36 eyes[J]. Ophthalmology, 2017, 124(5): 583-595. DOI: 10.1016/j.ophtha.2016.11.042.
16. Schwartz SG, Relhan N, O'Brien TP, et al. A complication associated with the use of prophylactic intracameral antibiotics: hemorrhagic occlusive retinal vasculitis[J]. Ophthalmology, 2017, 124(5): 578-579. DOI: 10.1016/j.ophtha.2017.01.038.
17. Todorich B, Faia LJ, Thanos A, et al. Vancomycin-associated hemorrhagic occlusive retinal vasculitis: a clinical-pathophysiological analysis[J]. Am J Ophthalmol, 2018, 188: 131-140. DOI: 10.1016/j.ajo.2018.01.030.
18. Matovic K, Mekjavic PJ, Groznik AL, et al. Vancomycin-associated hemorrhagic occlusive retinal vasculitis: a case series and systematic review[J]. Ophthalmic Surg Lasers Imaging Retina, 2022, 53(12): 702-712. DOI: 10.3928/23258160-20221026-03.
19. Mason RH, Ballios BG, Yan P, et al. Noninfectious endophthalmitis following intravitreal triamcinolone acetonide: clinical case and literature review[J]. Can J Ophthalmol, 2020, 55(6): 471-479. DOI: 10.1016/j.jcjo.2020.06.002.
20. Henry CR, Shah M, Barakat MR, et al. Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA)[J]. Br J Ophthalmol, 2022, 106(6): 802-806. DOI: 10.1136/bjophthalmol-2020-318019.
21. Barakat MR, Wykoff CC, Gonzalez V, et al. Suprachoroidal CLS-TA plus intravitreal aflibercept for diabetic macular edema: a randomized, double-masked, parallel-design, controlled study[J]. Ophthalmol Retina, 2021, 5(1): 60-70. DOI: 10.1016/j.oret.2020.08.007.
22. Zakaria YG, Salman AG, Said AMA, et al. Suprachoroidal versus intravitreal triamcinolone acetonide for the treatment of diabetic macular edema[J]. Clin Ophthalmol, 2022, 16: 733-746. DOI: 10.2147/OPTH.S351853.
23. Korobelnik JF, Kodjikian L, Delcourt C, et al. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France[J]. Graefe's Arch Clin Exp Ophthalmol, 2016, 254(12): 2307-2318. DOI: 10.1007/s00417-016-3394-y.
24. Rajesh B, Zarranz-Ventura J, Fung AT, et al. Safety of 6000 intravitreal dexamethasone implants[J]. Br J Ophthalmol, 2020, 104(1): 39-46. DOI: 10.1136/bjophthalmol-2019-313991.
25. Dobler E, Mohammed BR, Chavan R, et al. Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results[J]. Eye (Lond), 2023, 37(11): 2310-2315. DOI: 10.1038/s41433-022-02338-2.
26. Christensen LF, Hassing AK, Klefter ON, et al. Efficacy and safety of fluocinolone acetonide 0.19 mg intravitreal implant for the treatment of non-infectious uveitis: a systematic review of real-world evidence[J]. Ocul Immunol Inflamm, 2024, 33(4): 683-694. DOI: 10.1080/09273948.2024.2435472.
27. Daien V, Nguyen V, Essex RW, et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration[J]. Ophthalmology, 2018, 125(1): 66-74. DOI: 10.1016/j.ophtha.2017.07.005.
28. Williams PD, Chong D, Fuller T, et al. Noninfectious vitritis after intravitreal injection of anti-VEGF agents: variations in rates and presentation by medication[J]. Retina, 2016, 36(5): 909-913. DOI: 10.1097/IAE.0000000000000801.
29. Yang F, Hu R. Efficacy and safety of intravitreal conbercept and triamcinolone acetonide for wet age-related macular degeneration in China: a meta-analysis[J]. Int Ophthalmol, 2024, 44(1): 424. DOI: 10.1007/s10792-024-03346-9.
30. Baumal CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after Brolucizumab treatment[J]. Ophthalmol Retina, 2021, 5(6): 519-527. DOI: 10.1016/j.oret.2020.09.020.
31. Cozzi M, Ziegler A, Fasler K, et al. Sterile intraocular inflammation associated with faricimab[J]. JAMA Ophthalmol, 2024, 142(11): 1028-1036. DOI: 10.1001/jamaophthalmol.2024.3828.
32. Matsumoto H, Hoshino J, Numaga S, et al. Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration[J]. Jpn J Ophthalmol, 2024, 68(5): 531-537. DOI: 10.1007/s10384-024-01107-w.
33. Hashiya N, Maruko I, Miyaguchi Y, et al. Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report[J]. BMC Ophthalmol, 2025, 25(1): 42. DOI: 10.1186/s12886-024-03827-6.
34. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement[J]. Ophthalmology, 2002, 109(9): 1709-1716. DOI: 10.1016/s0161-6420(02)01125-9.
35. Zhou N, Xu X, Liu Y, et al. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma[J]. Eye (Lond), 2022, 36(7): 1448-1455. DOI: 10.1038/s41433-021-01657-0.
36. Razzaghpour N, Najafi A, Sabouri M R, et al. Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month study[J]. Med Hypothesis Discov Innov Ophthalmol, 2023, 12(3): 150-156. DOI: 10.51329/mehdiophthal1480.
37. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2017, 390(10097): 849-860. DOI: 10.1016/S0140-6736(17)31868-8.
38. Kiraly P, Cottriall CL, Taylor LJ, et al. Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center[J/OL]. Biomolecules, 2023, 13(10): 1484[2023-10-05]. https://pubmed.ncbi.nlm.nih.gov/37892166/. DOI: 10.3390/biom13101484.
39. He X, Cao W, Wang Z, et al. Efficacy evaluation of tissue plasminogen activator with anti-vascular endothelial growth factor drugs for submacular hemorrhage treatment: a meta-analysis[J/OL]. J Clin Med, 2023, 12(3): 1035[2023-01-29]. https://pubmed.ncbi.nlm.nih.gov/36769682/. DOI: 10.3390/jcm12031035.
40. Treumer F, Wienand S, Purtskhvanidze K, et al. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF[J]. Graefe's Arch Clin Exp Ophthalmol, 2017, 255(6): 1115-1123. DOI: 10.1007/s00417-017-3620-2.
41. Greenberg JP, Belin P, Butler J, et al. Aflibercept-related sterile intraocular inflammation outcomes[J]. Ophthalmol Retina, 2019, 3(9): 753-759. DOI: 10.1016/j.oret.2019.04.006.
42. Witkin AJ, Hahn P, Murray TG, et al. Occlusive retinal vasculitis following intravitreal Brolucizumab[J]. J Vitreoretin Dis, 2020, 4(4): 269-279. DOI: 10.1177/2474126420930863.
43. Mares V, Veloso C, Nehemy MB. Vancomycin-associated hemorrhagic occlusive retinal vasculitis masquerading as central retinal vein occlusion[J/OL]. Arq Bras Oftalmol, 2023, 87(4): e2022-2032[2023-03-24]. https://pubmed.ncbi.nlm.nih.gov/36995817/. DOI: 10.5935/0004-2749.2022-0132.
44. El Gendy HA. Vancomycin-associated retinal hemorrhages in pediatric age group: a case report[J/OL]. Am J Ophthalmol Case Rep, 2020, 20: 100880[2020-08-21]. https://pubmed.ncbi.nlm.nih.gov/32913922/. DOI: 10.1016/j.ajoc.2020.100880.
45. Nowroozzadeh MH, Hajipourkhorasani M. Increased risk of retinal vasculitis may be associated with aflibercept 8 mg: a pharmacovigilance analysis of the FAERS database[J]. Ocul Immunol Inflamm, 2025, 6: 1-3. DOI: 10.1080/09273948.2025.2476061.
46. Parakh S, Bhatt V, Das S, et al. Intraocular inflammation following intravitreal faricimab injection in neovascular age-related macular degeneration[J/OL]. Cureus, 2024, 16(12): e75937[2024-12-18]. https://pubmed.ncbi.nlm.nih.gov/39830553/. DOI: 10.7759/cureus.75937.
47. Lee YM, Gurung R, Gilhotra JS, et al. Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: a case report and review of literature[J]. Eye Vis (Lond), 2024, 11(1): 48. DOI: 10.1186/s40662-024-00416-y.
48. Perez Y, Neri P, Pichi F, et al. Multimodal imaging in retinal vasculitis[J]. Ophthalmologica, 2024, 247(4): 203-213. DOI: 10.1159/000540647.
49. Sharma A, Kumar N, Parachuri N, et al. Immunogenicity: clouding the future of intravitreal therapy[J]. Ocul Immunol Inflamm, 2023, 31(9): 1746-1749. DOI: 10.1080/09273948.2022.2139273.
50. Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals[J]. Ther Adv Drug Saf, 2011, 2(3): 113-128. DOI: 10.1177/2042098611406318.
51. Kim HM, Woo SJ. Immunogenicity and potential for intraocular inflammation of intravitreal anti-VEGF drugs[J/OL]. Curr Ther Res Clin Exp, 2024, 100: 100742[2024-03-14]. https://pubmed.ncbi.nlm.nih.gov/38617894/. DOI: 10.1016/j.curtheres.2024.100742.
52. Ghoraba HH, Akhavanrezayat A, Karaca I, et al. Ocular gene therapy: a literature review with special focus on immune and inflammatory responses[J]. Clin Ophthalmol, 2022, 16: 1753-1771. DOI: 10.2147/OPTH.S364200.
53. Chan YK, Dick AD, Hall SM, et al. Inflammation in viral vector-mediated ocular gene therapy: a review and report from a workshop hosted by the foundation fighting blindness, 9/2020[J]. Transl Vis Sci Technol, 2021, 10(4): 3. DOI: 10.1167/tvst.10.4.3.
54. Bucher K, Rodriguez-Bocanegra E, Dauletbekov D, et al. Immune responses to retinal gene therapy using adeno-associated viral vectors-implications for treatment success and safety[J/OL]. Prog Retin Eye Res, 2021, 83: 100915[2020-10-15]. https://pubmed.ncbi.nlm.nih.gov/33069860/. DOI: 10.1016/j.preteyeres.2020.100915.
55. Mehta N, Robbins DA, Yiu G, et al. Ocular inflammation and treatment emergent adverse events in retinal gene therapy[J]. Int Ophthalmol Clin, 2021, 61(3): 151-177. DOI: 10.1097/IIO.0000000000000366.
56. Menia NK, Alcibahy Y, Pichi F, et al. An update on noninfectious retinal vasculitis[J]. Ophthalmologica, 2024, 5: 1-14. DOI: 10.1159/000539608.
57. Lee K, Lee S, Jung S, et al. Analysis of ocular fluid in patients with ranibizumab-recalcitrant neovascular age-related macular degeneration who have serum anti-ranibizumab antibodies[J]. Graefe's Arch Clin Exp Ophthalmol, 2023, 261(12): 3581-3587. DOI: 10.1007/s00417-023-06146-6.
58. Diack C, Gibiansky L, Jaminion F, et al. Ocular pharmacokinetics of Faricimab following intravitreal administration in patients with retinal disease[J]. Transl Vis Sci Technol, 2024, 13(11): 14. DOI: 10.1167/tvst.13.11.14.
59. Yeung IY, Popp NA, Chan CC, et al. The role of sex in uveitis and ocular inflammation[J]. Int Ophthalmol Clin, 2015, 55(3): 111-131. DOI: 10.1097/IIO.0000000000000072.
60. Sen HN, Davis J, Ucar D, et al. Gender disparities in ocular inflammatory disorders[J]. Curr Eye Res, 2015, 40(2): 146-161. DOI: 10.3109/02713683.2014.932388.
61. Witkin AJ, Hahn P, Murray TG, et al. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis[J]. J Vitreoretin Dis, 2021, 5(4): 326-332. DOI: 10.1177/2474126420975303.
62. Hikichi T. Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation[J]. Graefe's Arch Clin Exp Ophthalmol, 2022, 260(8): 2529-2535. DOI: 10.1007/s00417-022-05611-y.
63. Eriş E, Perente I, Vural E, et al. Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema[J]. Int Ophthalmol, 2019, 39(7): 1575-1580. DOI: 10.1007/s10792-018-0977-0.
64. Lin D, Hu J, Wu K, et al. Synergistic effect of combined sub-tenon Triamcinolone and intravitreal anti-VEGF therapy for uveitic macular edema[J]. Drug Des Devel Ther, 2022, 16: 1055-1066. DOI: 10.2147/DDDT.S353251.
65. 张峥, 杨滢瑞. 年龄相关性黄斑变性玻璃体腔内注药术围术期基于微视频的回授法健康教育效果分析[J]. 河南外科学杂志, 2024, 30(4): 158-161.Zhang Z, Yang YR. Analysis of the health education effect based on micro-video feedback method during the perioperative period of intravitreal injection for age-related macular degeneration[J]. Henan Journal of Surgery, 2024, 30(4): 158-161.
66. Al Qassimi N, Kozak I, Al Karam M, et al. Management of diabetic macular edema: guidelines from the emirates society of ophthalmology[J]. Ophthalmol Ther, 2022, 11(5): 1937-1950. DOI: 10.1007/s40123-022-00547-2.
67. 中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病学组. 我国主要眼底病慢病管理专家共识[J]. 中华眼底病杂志, 2024, 40(4): 253-263. DOI: 10.3760/cma.j.cn511434-20240220-00076.Retinal Disease Group, Ophthalmology Branch of Chinese Medical Association, Retinal Disease Group, Ophthalmology Branch of Chinese Medical Doctor Association. National consensus on the management of major chronic fundus diseases in China: a modified Delphi approach[J]. Chin J Ocul Fundus Dis, 2024, 40(4): 253-263. DOI: 10.3760/cma.j.cn511434-20240220-00076.

Chinese Journal of Ocular Fundus Diseases

Expert consensus for the diagnosis and treatment of sterile intraocular inflammation after intraocular drug delivery (2025)

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content